NCT02201901 - Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis | Biotech Hunter

Enrollment

268

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg tablets administered orally once daily

DRUG

RBV

Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (50)

10016

New York

10029

New York

10032

New York

19104

Philadelphia

19107

Philadelphia

23502

Norfolk

28204

Charlotte

32256

Jacksonville

37211

Nashville

38138

Germantown

44195

Cleveland

46202

Indianapolis

46237

Indianapolis

71280

Monroe

76012

Arlington

87505

Santa Fe

90048

Los Angeles

Unknown

Phoenix

La Jolla

Los Angeles

Pasadena

San Francisco

Aurora

Washington D.C.

Gainesville

Miami

Tampa

Marietta

Chicago

Kansas City

New Orleans

Baltimore

Boston

Ann Arbor

Detroit

Rochester

Jackson

St Louis

Chapel Hill

Durham

Cleveland

Pittsburgh

Dallas

San Antonio

Murray

Fairfax

Richmond

Seattle

02905

Providence

00927

San Juan